GlassScriptPhysician profile
Brenda Mcfarlin
NPI 1699705855
$10,938.78
in general payments reported to CMS, 2019-2025
61 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,223 · 2022: $2,672 · 2023: $2,115 · 2024: $1,956 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,043.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,979.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,871.30 | 2021-2025 | |
| Amgen INC. | $762.89 | 2021-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $747.98 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Corcept Therapeutics | $654.06 | 2021-2025 | Korlym |
| Lilly USA, LLC | $474.36 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Mannkind Corporation | $275.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.96 | 2022-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $229.70 | 2021-2025 | Trintellix |
| Abbott Laboratories | $222.42 | 2021-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $187.80 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $162.30 | 2022-2025 | Minimed 780g |
| Antares Pharma, INC. | $159.52 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $156.56 | 2022-2025 | |
| Pfizer INC. | $154.00 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Mcfarlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.